BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 22, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

July 31, 2019

View Archived Issues

Outpatient draft eyes rate cut for Heartflow, but flat rates for Argus II

Read More

Head-to-head study demonstrates superiority of deep transcranial magnetic stimulation for MDD relief

Read More

Alliance aims to transform French health care system

Read More

Regulatory front

Read More

Appointments and advancements

Read More

Financings

Read More

Daily M&A

Read More

Other news to note

Read More

Product regulatory actions for July 30, 2019

Read More

BioWorld MedTech's Oncology Extra

Read More

Cantel buying Hu-Friedy in deal worth up to $775M

Cantel Medical Corp. is acquiring dental instruments and reprocessing specialist Hu-Friedy Mfg. Co. LLC for $725 million in upfront cash and stock considerations, plus up to $50 million in cash and stock earnouts tied to revenue milestones over the next 12 to 18 months. The deal, which is expected to close by Sept. 30, advances Cantel's goal of positioning itself as a major player in the global infection prevention and reprocessing workflow space for both dental and medical needs. Read More

Quanta scoops up £38M to back launch, submission

LONDON – Quanta Dialysis Technologies Ltd. has raised £38 million (US$46.7 million) in the first close of a series C round, to fund a U.S. FDA 510(k) submission and U.K. commercial launch of its SC+ home hemodialysis system. With the cash now in hand, both these events are due to occur before the end of 2019. "We've got a lot of work to do," said John Milad, CEO of Quanta. "This is the rocket fuel." Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Microscopic view of the ebola virus

    WHO declares Ebola outbreak a public health emergency of international concern

    BioWorld
    The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing